SOTAC2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member SOTAC2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares SOTAC 2023-04-01 2024-03-31 INR Yearly true Cash Flow Indirect Audited Standalone 339925000.00 7991000.00 347916000.00 220470000.00 16932000.00 -2085000.00 12214000.00 4784000.00 14137000.00 39939000.00 306391000.00 41525000.00 -2338000.00 39187000.00 0.00 39187000.00 11159000.00 -710000.00 10449000.00 28738000.00 0.00 0.00 0.00 28738000.00 28738000.00 110500000.00 10 2.60 2.60 0.00 0.00 0.00 [1] The above standalone financial results for the Half Year Ended and Financial Year Ended on March 31, '24 have been prepared by the Company in accordance with regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the board of directors in their meeting held on 17th May, '24. [2] Previous Year's /period's figures have been regrouped/rearranged/ restated/adjusted/rectified wherever considered necessary. [3]The standalone audited financial results are prepared in accordance with the Accounting Standards Prescribed urder Section 133 of the Companies Act,2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable [4]The statement includes the results for the half year ended 31st March, '24 being the balanced figure between audited figures in respect of the full financial year and the un-audited figures in respect of 1st half year of the current financial year (23-24). [5]During the last quarter, company has acquired 3,00,000 equity shares of Sotac Life Science Private Limited The Subsidiary having face value of Rs. 10/- each fully paid up for cash at the price of Rs. 10/- per equity share (share premium - NIL) aggregating to Rs.30.00/- Lakhs. [6] In accordance with regulation 33 of SEBI (LODR) Regulation 2015, the above results have been reviewed by the Statutory Auditors of the Company. [7] Company is mainly engaged in manufacturing of of a wide range of pharmaceutical products such as Non Beta-Lactam (general) tablets, Non Beta-Lactam (general) capsules, Non Beta-lactam Syrup and external preparations looking into the nature of business company is operating under single segment hence segment reporting is not applicable to Company. [8] The Status of investor's complaints during the year ended on March 31,'24 as under:- Complaints pending at the beginning of the period Nill Complaints received during the period Nill Complaints disposed during the period Nill Complaints resolved at the end of the period Nill Audited Standalone 671050000.00 13187000.00 684237000.00 421080000.00 26158000.00 4761000.00 26568000.00 10134000.00 25111000.00 90536000.00 604348000.00 79889000.00 -2338000.00 77551000.00 0.00 77551000.00 20885000.00 -822000.00 20063000.00 57488000.00 0.00 0.00 0.00 574.88 57488000.00 110500000.00 10 372244000.00 5.24 5.24 0.00 0.00 0.00 other expenses 39939000.00 other expenses 90536000.00 10134000.00 25111000.00 0.00 0.00 0.00 0.00 0.00 -22942000.00 0.00 0.00 12303000.00 -14422000.00 -105158000.00 -71384000.00 -34453000.00 -18609000.00 -12215000.00 -256241000.00 -243938000.00 -166387000.00 0.00 0.00 -10622000.00 20885000.00 0.00 -197894000.00 0.00 0.00 -197894000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 60977000.00 91000.00 0.00 0.00 0.00 0.00 0.00 0.00 10622000.00 0.00 -75031000.00 0.00 -125295000.00 0.00 0.00 -125295000.00 238295000.00 0.00 0.00 26921000.00 21841000.00 0.00 10134000.00 0.00 381000.00 233622000.00 0.00 0.00 233622000.00 -89567000.00 0.00 -89567000.00 95984000.00 6417000.00